Antibacterial drug resistance is the process that bacteria use to tolerate and overcome the effects of antibiotic drugs. Resistance can arise through mutations or can be acquired from other bacteria through plasmids.
This report contains market size and forecasts of Antibacterial (Drug) Resistance in global, including the following market information:
Global Antibacterial (Drug) Resistance Market Revenue, 2017-2022, 2023-2028, ($ millions)
Download FREE Sample of this Report @ https://www.statsmarketresearch.com/download-free-sample/7164737/global-antibacterial-resistance-2022-2028-626
Global Antibacterial (Drug) Resistance Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Antibacterial (Drug) Resistance companies in 2021 (%)
The global Antibacterial (Drug) Resistance market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Telavancin (Vibativ) Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Antibacterial (Drug) Resistance include Melinta Therapeutics, Allergan, Merck, Abbott Laboratories, Pfizer, GSK, PENDOPHARM, Absynth Biologics and Achaogen, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Antibacterial (Drug) Resistance manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Antibacterial (Drug) Resistance Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Antibacterial (Drug) Resistance Market Segment Percentages, by Type, 2021 (%)
Telavancin (Vibativ)
Ceftaroline Fosamil (Teflaro/ Zinforo)
Fidaxomicin (Dificid / Dificlir)
Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
Dalbavancin (Dalvance/ Xydalba)
Tedizolid Phosphate (Sivextro)
Oritavancin (Orbactiv/ Nuvocid)
Ceftolozane-Tazobactam (Zerbaxa)
Ceftazidime-Avibactam (Avycaz/ Zavicefta)
PHASE III DRUGS
Global Antibacterial (Drug) Resistance Market, by Indication, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Antibacterial (Drug) Resistance Market Segment Percentages, by Indication, 2021 (%)
Complicated Urinary Tract Infection (CUTI)
Complicated Intra-Abdominal Infections (CIAI)
Blood Stream Infections (BSI)
Clostridium Difficile Infections (CDI)
Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
Community Acquired Bacterial Pneumonia (CABP)
Global Antibacterial (Drug) Resistance Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Antibacterial (Drug) Resistance Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Antibacterial (Drug) Resistance revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Antibacterial (Drug) Resistance revenues share in global market, 2021 (%)
Key companies Antibacterial (Drug) Resistance sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Antibacterial (Drug) Resistance sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Melinta Therapeutics
Allergan
Merck
Abbott Laboratories
Pfizer
GSK
PENDOPHARM
Absynth Biologics
Achaogen
Acino Holdings
Aventis Pharma
Austell Laboratories
Assembly Biosciences
Arpida
Demuris
Evolva Holding
ContraFect
Cerexa
InterMune
Isis Pharmaceuticals
Lyndra
Microbecide
Morphochem
Nabriva Therapeutics
NanoSafe Coatings
Novexel
Osel
VenatoRx Pharmaceuticals
AAIPharma Services
ANTABIO
Table of content
1 Introduction to Research & Analysis Reports
1.1 Antibacterial (Drug) Resistance Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Indication
1.3 Global Antibacterial (Drug) Resistance Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Antibacterial (Drug) Resistance Overall Market Size
2.1 Global Antibacterial (Drug) Resistance Market Size: 2021 VS 2028
2.2 Global Antibacterial (Drug) Resistance Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Antibacterial (Drug) Resistance Sales: 2017-2028
3 Company Landscape
3.1 Top Antibacterial (Drug) Resistance Players in Global Market
3.2 Top Global Antibacterial (Drug) Resistance Companies Ranked by Revenue
3.3 Global Antibacterial (Drug) Resistance Revenue by Companies
3.4 Global Antibacterial (Drug) Resistance Sales by Companies
3.5 Global Antibacterial (Drug) Resistance Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Antibacterial (Drug) Resistance Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Antibacterial (Drug) Resistance Product Type
3.8 Tier 1, Tier 2 and Tier 3 Antibacterial (Drug) Resistance Players in Global Market
3.8.1 List of Global Tier 1 Antibacterial (Drug) Resi
CONTACT US:
276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170 / +91 8087042414
Visit: https://www.statsmarketresearch.com/
Similar Reports: Antibacterial (Drug) Resistance Market – Global Outlook and Forecast 2021-2027
Global and United States Antibacterial (Drug) Resistance Market Insights, Forecast to 2027
Global Antibacterial (Drug) Resistance Market Research Report 2021
